吉林长龙药业(08049.HK)在过去3年不慎违反上市规则 未有公布认购理财产品协议
吉林长龙药业(08049.HK)公布,在2018年1月17日至2020年12月29日期间,曾认购93份理财产品,但未有公布,不慎违反GEM上市规则。
公司指,就2019年及2020年的大部分违反情况而言,违反GEM上市规则乃由於公司管理层对银保监会於2018年9月颁布的该办法有所误解,而导致不慎违反。
公司在发现不合规情况後,已即时通知负责合规事宜的相关员工确保保本产品正确分类,并提醒相关员工向内部审核及监控部报告理财产品的认购/还款,以确保相关交易符合GEM上市规则的相关披露规定。负责投资理财产品及GEM上市规则合规事宜的相关员工现时已完全清楚有关分类及GEM上市规则的规定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.